Veru Inc (NASDAQ: VERU), an oncology and urology focused biopharmaceutical Company developing novel therapeutics for the treatment of prostate cancer, announced the initiation of a pivotal Phase 2 clinical trial of VERU-111, a first-in-class, oral, selective antitubulin agent, intended for the treatment of metastatic castration...
AzurRx BioPharma (NASDAQ: AZRX), a development stage company that is developing oral, nonsystemic, recombinant proteins for the treatment of gastrointestinal diseases, announced the results from a Phase II Clinical Trial of MS1819. The phase II trial named OPTION was an open-label, crossover trial being carried...
Severe combined immunodeficiency (SCID) or “Bubble Boy Syndrome” is a rare genetic disorder caused by gene mutations that inhibit the functioning of immune cells. Children afflicted with this condition are healthy in appearance but are susceptible to severe infections, even a common cold can prove...
Human Immunodeficiency Virus (HIV) compromises the body’s immunity by attacking CD4 cells (a type of T cell), exposing it to a host of infections and diseases and ultimately leading to the development of AIDS. According to data provided by Centres for Disease Control and Prevention,...
Mustang Bio’s (NASDAQ: MBIO) shares rose by almost 250% after its development partner, St Jude Children’s Research Hospital in Memphis, published study results that demonstrated that its experimental gene therapy could cure “Bubble Boy” disease or X-SCID, a severe combined immunodeficiency in infants. Figure 1 - Stock...
